Senti Biosciences, Inc. is a biotechnology company focused on developing innovative cell and gene therapies using its proprietary platform to enhance the therapeutic potential of engineered cells
The company utilizes advanced synthetic biology techniques to create intelligent and programmable therapies designed to target specific diseases with greater precision. By harnessing the power of genetic engineering, Senti aims to address unmet medical needs, particularly in the areas of cancer and other serious conditions, ultimately improving patient outcomes through its cutting-edge research and development initiatives.
Senti Biosciences shares are trading higher by 102.6% during Monday's session. The company was awarded $8 million from the California Institute for Regenerative Medicines.
Senti Biosciences Inc (NASDAQSNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato
